LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Sage Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

9.17 -0.97

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.16

Max

9.27

Galvenie mērījumi

By Trading Economics

Ienākumi

34M

-62M

Pārdošana

1.2M

14M

EPS

-0.998

Peļņas marža

-442.395

Darbinieki

353

EBITDA

13M

-67M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

-4.53% downside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 30. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

96M

582M

Iepriekšējā atvēršanas cena

10.14

Iepriekšējā slēgšanas cena

9.17

Ziņu noskaņojums

By Acuity

100%

0%

364 / 380 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Sage Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 27. jūn. 20:51 UTC

Peļņas

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025. g. 27. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 27. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 27. jūn. 20:48 UTC

Tirgus saruna

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

2025. g. 27. jūn. 20:46 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 27. jūn. 20:46 UTC

Tirgus saruna

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

2025. g. 27. jūn. 19:31 UTC

Tirgus saruna

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

2025. g. 27. jūn. 19:19 UTC

Tirgus saruna

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

2025. g. 27. jūn. 19:16 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025. g. 27. jūn. 18:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 27. jūn. 18:42 UTC

Tirgus saruna

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

2025. g. 27. jūn. 18:39 UTC

Tirgus saruna
Peļņas

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

2025. g. 27. jūn. 18:29 UTC

Tirgus saruna

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

2025. g. 27. jūn. 18:18 UTC

Tirgus saruna

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

2025. g. 27. jūn. 18:16 UTC

Tirgus saruna

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

2025. g. 27. jūn. 17:16 UTC

Tirgus saruna

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

2025. g. 27. jūn. 17:08 UTC

Peļņas

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

2025. g. 27. jūn. 16:52 UTC

Iegādes, apvienošanās, pārņemšana

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

2025. g. 27. jūn. 16:22 UTC

Peļņas

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 27. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 27. jūn. 15:59 UTC

Tirgus saruna

Gold Futures Slump on Improving Risk Appetite -- Market Talk

2025. g. 27. jūn. 15:56 UTC

Tirgus saruna

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Salīdzinājums

Cenas izmaiņa

Sage Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

-4.53% uz leju

Prognoze 12 mēnešiem

Vidējais 8.86 USD  -4.53%

Augstākais 12 USD

Zemākais 5 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sage Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

15 ratings

1

Pirkt

13

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 7.285Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Neutral Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.